{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-009146","form_type":"8-K","ticker":"PMI","cik":"0002030617","company_name":"Picard Medical, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.389599+00:00","generated_at":"2026-05-16T19:58:08.619317+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Picard Medical Q3 revenue up 35% to $1.19M; IPO nets $15.5M in September","bullets":["Revenue $1.19M (+35% YoY); gross loss narrowed 81% to $0.13M; operating loss $3.36M vs $3.77M.","Net loss $22.7M includes $12.4M non-cash derivative revaluation charge upon IPO debt conversion.","IPO completed Sept 2: $19.5M gross proceeds ($15.5M net); retired convertible debt.","Appointed independent directors Sam Van and George Ye; patent granted for next-gen Emperor artificial heart.","Year-to-date revenue $3.93M (+11%); operating loss $10.3M; EPS ($0.96) vs ($1.79) prior."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-009146","json":"https://secwatch.observer/filing/0001829126-25-009146.json","markdown":"https://secwatch.observer/filing/0001829126-25-009146.md","text":"https://secwatch.observer/filing/0001829126-25-009146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912625009146/0001829126-25-009146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912625009146/picardmedical_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:58:08.619317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}